Innovating and accelerating the development of new cancer therapies to address unmet medical needs
The preclinical development process for cancer therapies needs to be revolutionized. Oncode Accelerator is boldly taking on this challenge, driven by a profound commitment to improving patient outcomes.
Our Approach
To accelerate the development of safe, personalized and effective therapies, Oncode Accelerator places the patient at the center of the preclinical development pipelines. We do this by fully utilizing the power of three innovation Platforms: well-defined Patient Cohorts, patient-derived Organoid models and Artificial Intelligence.
We integrate expertise from our innovation Platforms into the drug development process to accelerate the development of four key types of therapies that benefit our society: Small Molecules, Biologics, Cell & Gene Therapy, and Therapeutic Vaccines. These four types of therapies make up our Workstreams.
Work with us
Through Demonstrator Projects, we invite international cancer researchers and drug developers from across academia and industry to collaborate with us on the preclinical development of promising targets.
Demonstrator Projects test and validate part of the innovated Oncode Accelerator infrastructure while simultaneously aiming to increase the technology readiness level of oncology assets, and ultimately aim to deliver novel clinical candidates.
Our mission
We aim to collaboratively optimize and accelerate the development of
new cancer therapies for the benefit of patients of all ages.
Subscribe to stay connected
Click here to subscribe
Oncode Accelerator News
-
Oncode Accelerator Strengthens Alignment with Oncode Institute Through Leadership Change
Today, the Oncode Accelerator Foundation announced that Arnoud Huisman will step down as CEO and Chair of the Board of Directors as of 1 April. To further strengthen strategic alignment with Oncode Institute, Bertholt Leeftink, Managing Director of Oncode Institute, has been appointed as the new CEO and Chair of the Board of Directors of the Oncode Accelerator Foundation. Going forward, Bertholt will lead both organizations, which have distinct focus areas within a shared mission. -
TNO: Innovation In Action
As a partner of Oncode Accelerator, TNO brings world-class translational technology and AI-driven insights to the oncology ecosystem. We spoke with Principal Scientist Wouter Vaes and Senior Scientist Jennifer McCormack-Venhorst to explore how TNO’s unique mix of tech and knowledge can enable safer, faster and more predictive cancer drug development so that better therapies reach patients sooner. -
Bringing Patient Biology into Early Drug Development
Chief Development Officer Clare Doris and Executive in Residence Tilly Bingham of Cumulus Oncology each have over 20 years of experience working across different areas of drug discovery and development. During their career trajectories spanning big pharma, global CROs, and biotech start-ups, they’ve seen what it takes to develop a successful therapy. When it comes to developing a drug that can bring meaningful impact for patients, Clare and Tilly know that promising cancer drugs can falter if patient selection — identifying which patients will benefit — is addressed too late. This awareness, and their ambition to do better, is what led Cumulus Oncology to partner with Oncode Accelerator.
Oncode Accelerator Scientific Publications
Oncode Accelerator Facts
Oncode Accelerator is a public-private partnership that is funded by the Dutch National Growth Fund (NGF). It is a collaboration between six coordinating partners: Leiden University, Leiden University Medical Center, the Netherlands Cancer Institute, Princess Máxima Center, UMC Utrecht and the Oncode Accelerator Foundation.
325M €
The Dutch National Growth Fund invested 325 million euros in our program. Of this, €161 million was granted in Phase 1, €123 million in Phase 2, and €41 million as a conditional grant.
6
Oncode Accelerator has 6 coordinating partners. All program coordinating partners lead individual Workstreams and Platforms within the wider Oncode Accelerator program.
35 +
Oncode Accelerator is a dynamic collaboration of more than 35 public and private partners from different corners of the oncology ecosystem. Oncode Accelerator is an initiative with an open nature, we welcome new partners to apply for Demonstrator Projects and work with us.
1.5M €
We co-fund up to 1.5 million euros for each Demonstrator Project. Through Demonstrator Projects, we test and validate the innovated Oncode Accelerator infrastructure while simultaneously aiming to increase the technology readiness level of promising leads - to ultimately benefit patients.
